On October 20-21, VPEIF2021 (13th) Fogo Pharmaceutical Engineering International Forum was grandly held in Taizhou, Jiangsu · China Medical City Convention and Exhibition Center. At the meeting, the "2020 White Paper on China's Biopharmaceutical Industry" (hereinafter referred to as the "White Paper") jointly produced by Jigong Fogo and Mitu Consulting was officially released. With the T-EPC model, Tianjushi Group has successfully selected high-quality development cases to promote the intelligent transformation of biopharmaceutical factories, becoming the only company in the field of medical engineering services that has been selected for the white paper.

Driven by technological progress, industrial restructuring, and increased consumption and payment capabilities, China's biomedicine market has shown a steady upward trend. From 2016 to 2020, the overall scale of my country's biomedicine market has increased from RMB 183.6 billion to RMB 387 billion, with an average annual compound growth rate of 20%. It is estimated that in 2025, the overall scale of my country's biopharmaceutical market will reach 833.2 billion yuan. In this context, Fogo Industrial Media has joined hands with professional consulting companies and organized authoritative experts to participate in a comprehensive survey of pharmaceutical companies, and form the results of the "White Paper on China's Biopharmaceutical Industry in 2020". It aims to gather industrial wisdom, help people in the pharmaceutical industry at home and abroad understand the development status and trends of China's biopharmaceutical market, and provide reference and enlightenment for building an industrial development pattern. After the Chinese version of the white paper is released, it will be translated into English and German and released more than 40,000 copies worldwide, and will be simultaneously published in PROCESS and Pharm.TCE magazines.

In the chapter of "China Biopharmaceutical Production Line Design and Integration and Intelligent Transformation" in the white paper, Tianjushi Group is selected as a typical company for case analysis, which affirms the relevant aspects of Tianjushi's biopharmaceutical production line design and integration. Advantages and results achieved.

Tianjushi Group has been in the pharmaceutical industry for many years. It has Grade A design in the chemical, petrochemical and pharmaceutical industry, Grade A design in the construction industry, Grade A consulting letter for engineering consulting units, Grade 1 general contracting of mechanical and electrical engineering construction, and Grade 1 professional contracting of electronic and intelligent engineering. With a number of design and construction qualifications, it has successively served more than 50 national 100 compulsory pharmaceutical companies, with projects covering more than 20 provinces, cities, and autonomous regions across the country. In recent years, the focus on the biomedical industry has achieved remarkable results. In 2019, the Shanghai Design and Research Institute of Tianjushi Group was established. The general contracting section of Tianjushi Biomedicine led by Ding Zhijie, Dong Wenliang, Qiu Jifu and other biomedical engineering design experts has outstanding performance. It has served Junshi Bio, Kangsino, Many leading companies in biopharmaceuticals, including WuXi Microbiology, WuXi Biosciences, Harmonicare Biopharmaceuticals, and Maiwei Biopharmaceuticals, specialize in large-molecule biopharmaceuticals and high-activity products, especially in new types of monoclonal antibodies, vaccines, insulin, cell therapy, and gene therapy. There are industry representative cases in the field of biological preparations; in 2021, Tianjushi Group and the internationally renowned consulting company CB Consultancy AG (hereinafter referred to as "CBC") reached an in-depth strategic cooperation, and Christian Bachofen, the founder of CBC and an internationally renowned expert in biomedicine design and planning The Chief Technology Officer of Biomedicine of Tianjushi Group, marking Tianjushi has entered a new stage of development in the field of biomedical EPC services.

All the past is the prologue, and all the future is hopeful. In the era of drastic changes in the biopharmaceutical industry, we believe that the upstream industry chain represented by the times will continue to anchor the foundation, face the industrial revolution characterized by digital transformation, and continue to provide biopharmaceutical companies with more advanced and advanced technologies. Intelligent one-stop engineering service. Challenge, practice, innovate, and share again. Together with customers, we will create a new future and bloom more excitingly.